10 Most Profitable Biotech Stocks to Invest in Now

4. Argenx SE (NASDAQ:ARGX)

TTM Net Income: $1.06 billion

Number of Hedge Fund Holders: 54

Argenx SE (NASDAQ:ARGX) is one of the most profitable biotech stocks to invest in now. On July 8, Deutsche Bank analyst Emmanuel Papadakis upgraded Argenx SE (NASDAQ:ARGX) to Buy from Hold with a EUR 550 price target.

Argenx SE (NASDAQ:ARGX) reported that it generated global product net sales of $790 million in Q1 2025, inclusive of both VYVGART and VYVGART SC.

The company also exhibited strong underlying fundamentals across key patient and prescriber metrics, with 99% product net sales growth year-over-year compared to Q1 2024, along with a 7% product net sales growth from Q4 2024.

Argenx SE (NASDAQ:ARGX) is a biotech company that develops treatments for severe autoimmune diseases. The company operates through four segments: the United States, Japan, EMEA, and China.